CA2959207A1 - Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine - Google Patents
Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine Download PDFInfo
- Publication number
- CA2959207A1 CA2959207A1 CA2959207A CA2959207A CA2959207A1 CA 2959207 A1 CA2959207 A1 CA 2959207A1 CA 2959207 A CA2959207 A CA 2959207A CA 2959207 A CA2959207 A CA 2959207A CA 2959207 A1 CA2959207 A1 CA 2959207A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- cytokine
- subject
- antigenic molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201415247A GB201415247D0 (en) | 2014-08-28 | 2014-08-28 | Compound and method |
| GB1415247.4 | 2014-08-28 | ||
| GB201420773A GB201420773D0 (en) | 2014-11-21 | 2014-11-21 | Compound and method |
| GB1420773.2 | 2014-11-21 | ||
| PCT/EP2015/069794 WO2016030529A1 (en) | 2014-08-28 | 2015-08-28 | Compound and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2959207A1 true CA2959207A1 (en) | 2016-03-03 |
| CA2959207C CA2959207C (en) | 2024-09-10 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| JP7079819B2 (ja) | 2022-06-02 |
| AU2015308345B2 (en) | 2020-12-10 |
| JP2020182486A (ja) | 2020-11-12 |
| CN108136016A (zh) | 2018-06-08 |
| EP3185901A1 (en) | 2017-07-05 |
| KR102678732B1 (ko) | 2024-06-25 |
| EP3185901C0 (en) | 2023-10-04 |
| NZ729408A (en) | 2021-12-24 |
| KR20170047336A (ko) | 2017-05-04 |
| US10537639B2 (en) | 2020-01-21 |
| WO2016030529A1 (en) | 2016-03-03 |
| AU2015308345B9 (en) | 2020-12-24 |
| BR112017003486A2 (pt) | 2018-01-16 |
| US20170252441A1 (en) | 2017-09-07 |
| JP2017526371A (ja) | 2017-09-14 |
| AU2015308345A1 (en) | 2017-03-16 |
| EP3185901B1 (en) | 2023-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3038619B1 (en) | Compound and method for vaccination and immunisation | |
| US10556929B2 (en) | Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection | |
| CA2922467A1 (en) | Oncology vaccine | |
| EP3265120B1 (en) | Method | |
| AU2018229741A1 (en) | Peptides and methods for the treatment of diabetes | |
| CA2811957A1 (en) | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents | |
| JP2017509642A (ja) | 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬 | |
| JP7079819B2 (ja) | 化合物および方法 | |
| US20160040128A1 (en) | Method | |
| CA2945220C (en) | Method of treating melanoma | |
| WO2015028575A1 (en) | Immunisation method by photochemical internalisation | |
| CA2959207C (en) | Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine | |
| WO2016030528A1 (en) | Compound and method | |
| CA2557654A1 (en) | Peptides of il1 beta and tnf alpha and method of treatment using same | |
| US20220054631A1 (en) | MHC Class I Associated Hepatitis B Peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200821 |
|
| EEER | Examination request |
Effective date: 20200821 |
|
| EEER | Examination request |
Effective date: 20200821 |
|
| EEER | Examination request |
Effective date: 20200821 |
|
| EEER | Examination request |
Effective date: 20200821 |
|
| EEER | Examination request |
Effective date: 20200821 |
|
| EEER | Examination request |
Effective date: 20200821 |
|
| EEER | Examination request |
Effective date: 20200821 |
|
| EEER | Examination request |
Effective date: 20200821 |
|
| EEER | Examination request |
Effective date: 20200821 |
|
| EEER | Examination request |
Effective date: 20200821 |